Biodesix, Inc. ( (BDSX) ) has released its Q1 earnings. Here is a breakdown of the information Biodesix, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biodesix, Inc. is a diagnostic solutions company specializing in lung disease diagnostics and services, aiming to improve clinical care and patient outcomes. In the first quarter of 2025, Biodesix reported a revenue of $18.0 million, marking a 21% increase from the previous year, with gross margins reaching 79.4%. The company also noted an 18% improvement in net loss compared to the same period last year. Key financial metrics revealed a significant growth in diagnostic testing and development services, contributing to the overall revenue increase. The company also highlighted a strategic reconfiguration of its sales team to enhance market reach, which is expected to bolster long-term growth. Looking ahead, Biodesix has updated its revenue guidance for 2025 to a range of $80-85 million, with expectations of achieving adjusted EBITDA positivity by the fourth quarter, reflecting a positive outlook for continued financial and operational improvements.